Vanda Pharmaceuticals Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Vanda Pharmaceuticals Inc. on April 23, 2018, reporting an event that occurred on April 18, 2018. The filing addresses a change in the company's executive leadership.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes rather than financial performance.
Material Changes
On April 18, 2018, Richard L. Gulino notified the Company of his resignation as Senior Vice President, General Counsel, and Secretary. His resignation is effective May 2, 2018. The departure is for personal endeavors and is not the result of any disagreement with the Company regarding its operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future performance. No specific risks or contingencies related to the resignation were disclosed beyond the standard statement that the departure was amicable.
Key Facts for Investor Verification
- Richard L. Gulino is resigning from his roles as Senior Vice President, General Counsel, and Secretary.
- The resignation becomes effective on May 2, 2018.
- The departure is voluntary and unrelated to any disputes with the Company.
- James P. Kelly, Executive Vice President, Chief Financial Officer, and Treasurer, signed the report.